By Fineline Cube 
Novo Nordisk A/S (NYSE: NVO) announced that its innovative, long‑acting human growth hormone Sogroya (generic name: somapacitan injection) was approved by China’s National Medical Products Administration (NMPA) on 8 September 2026 for three new indications: growth failure in pediatric patients aged 2.5 years and older with Noonan syndrome (NS), with idiopathic short stature (ISS), and with short stature born small for gestational age (SGA) who failed to show catch‑up growth by 2 years of age. Building on its existing indication for pediatric growth hormone deficiency (GHD), the triple approval makes Sogroya the long‑acting growth hormone with the broadest set of approved indications in China to date.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Three new pediatric indications |
| Product | Sogroya (somapacitan injection) – long‑acting human growth hormone |
| Approval Date | 8 September 2026 (announced 10 September 2026) |
| New Indication 1 | Growth failure in pediatric patients ≥ 2.5 years with Noonan syndrome (NS) |
| New Indication 2 | Pediatric patients ≥ 2.5 years with idiopathic short stature (ISS) |
| New Indication 3 | Pediatric patients ≥ 2.5 years born small for gestational age (SGA) with short stature who failed to show catch‑up growth by 2 years of age |
| Existing Indication | Pediatric growth hormone deficiency (GHD) |
| Next Steps | Commercial rollout in China; pricing and reimbursement: Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: Somapacitan, a long‑acting recombinant human growth hormone administered by subcutaneous injection under the brand Sogroya.
- Long‑Acting Design: Engineered for once‑weekly dosing, replacing the daily injections required by conventional somatropin therapy — a key driver of treatment adherence in pediatric populations.
- Mechanism: Somapacitan replaces or supplements endogenous growth hormone, stimulating linear growth through the growth hormone/IGF‑1 axis in children with growth failure of diverse etiologies.
- Label Breadth: With the three new approvals added to pediatric GHD, Sogroya now covers four pediatric growth‑failure indications in China — the broadest approved label among long‑acting growth hormones in the market.
Indication Landscape – Three New Pediatric Populations
- Noonan Syndrome (NS): A genetic disorder frequently accompanied by short stature; growth hormone therapy is an established intervention for NS‑related growth failure. China‑specific prevalence: Not disclosed.
- Idiopathic Short Stature (ISS): A diagnosis of exclusion covering children significantly below normal height without an identifiable endocrine, genetic, or systemic cause — one of the largest segments of pediatric short‑stature clinic populations.
- Small for Gestational Age (SGA): Children born below the normal weight/length threshold for gestational age who fail to show catch‑up growth by 2 years of age, a population at persistent risk of adult short stature absent intervention.
- Common Age Floor: All three indications apply to pediatric patients aged 2.5 years and older, aligning the label across the new populations.
Market Impact & Outlook
- Label‑Leadership Positioning: Holding the broadest long‑acting growth hormone label in China gives Novo Nordisk a decisive formulary and prescribing advantage over both daily somatropins and competing weekly agents as China’s long‑acting GH market matures.
- Adherence Economics: Weekly dosing addresses the principal limitation of pediatric GH therapy — daily injection burden — supporting persistence across the multi‑year treatment courses typical for NS, ISS and SGA.
- China Pediatric Growth Market: Rising diagnosis rates of short stature, expanding pediatric endocrinology capacity, and growing parental willingness to treat make China one of the fastest‑growing growth‑hormone markets globally. Market‑size figures: Not disclosed in the announcement.
- Franchise Expansion: The triple approval deepens Novo Nordisk’s (NYSE: NVO) rare‑disease and pediatric endocrinology footprint in China, complementing Sogroya’s existing GHD franchise and strengthening hospital‑channel relationships.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercialization of the newly approved indications for Sogroya in China, pricing and reimbursement outcomes, market adoption, and competitive expectations. Actual results may differ materially due to risks including payer negotiations, competitive entry by other long‑acting growth hormones, supply constraints, and evolving pediatric treatment guidelines.-Fineline Info & Tech